Stonemor Inc
Change company Symbol lookup
Select an option...
STON Stonemor Inc
$NQDM15LMCADN Nasdaq Developed Markets Telecommuni
BFZ BlackRock California Municipal Income Trust
CAR Avis Budget Group Inc
GIS General Mills Inc
VLN Valens Semiconductor Ltd
CIF MFS? Intermediate High Income Fund
LVOXW LiveVox Holdings Inc *W EXP 06/18/2026
SASR Sandy Spring Bancorp Inc
SWKH SWK Holdings Corp

Consumer Discretionary : Diversified Consumer Services | Small Cap Value
Company profile

Stonemor Inc. is a provider of funeral and cemetery products and services in the death care industry. The Company's segments include Cemetery Operations and Funeral Home Operations. Cemetery Operations segment consists of sale of cemetery merchandise, which includes markers, bases, vaults, caskets and cremation niches and its cemetery services, which include opening and closing services, cremation services and fees for the installation of cemetery merchandise. Funeral Home Operations segment consists of sales of funeral home merchandise, which includes caskets and other funeral related items and service, which include services such as family consultation, the removal of and preparation of remains and the use of funeral home facilities for visitation and prayer services. Funeral Home Operations segment also include the sale of term and whole life insurance on an agency basis, in which it earn a commission from the sales of these insurance policies.

Closing Price
Day's Change
-0.02 (-0.79%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Giving Moderna's COVID-19 booster at the same time as Sanofi's flu is safe and effective

10:38 am ET October 8, 2021 (MarketWatch)

U.S.-listed shares of Sanofi (SAN.FR) gained 0.4% in trading on Friday after it announced that co-administering a flu shot with Moderna Inc.'s (MRNA) experimental COVID-19 booster in seniors is safe and effective. Moderna's stock was down 2.7%. The interim findings came from a study of about 300 participants, and they showed a similar immune response and safety signal when giving the shots at the same time compared with giving the shots separately. Sanofi's flu shot, Fluzone High-Dose Quadrivalent, is approved in the U.S. for people who are 65 years old and older. Moderna's booster candidate is currently under review for emergency authorization at the Food and Drug Administration. So far this year, Sanofi's stock has gained 0.5% and Moderna shares have soared 187.8%, while the broader S&P 500 is up 16.1%.

-Jaimy Lee


(END) Dow Jones Newswires

October 08, 2021 10:38 ET (14:38 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.